Mangalam Drugs & Organics Ltd. (MANGALAM) AI Stock Analysis

• Market Cap: ₹519.48M
• Dividend Yield: N/A
• Average Volume (3M): 5.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.22
• Revenue Growth: -24.55%
• EPS Growth: -310.57%
• Country: IN
• Employees: 432
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -4.64
• Shares Outstanding: 15,828,248
• 10 Day Avg. Volume: 11,101
• 30 Day Avg. Volume: 5,111
• PEG Ratio: -0.11
• Price to Book (P/B): 0.84
• Price to Sales (P/S): 0.39
• P/FCF Ratio: 5.56
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: ₹39.00 ▲(38.94% Upside)

The overall stock score of 45 reflects significant challenges faced by Mangalam Drugs & Organics Ltd. The most impactful factor is the negative valuation due to unprofitability and lack of dividend yield. Technical analysis indicates a strong bearish trend, further weighing down the score. Financial performance shows mixed results, with particular concerns around profitability and cash flow stability.

Positive Factors

Business Model Strength

The company's focus on APIs and intermediates provides a stable revenue base, leveraging demand from pharmaceutical firms, ensuring long-term contracts and market stability.

Regulatory Compliance

Commitment to regulatory compliance and quality enhances reputation, enabling competitive pricing and securing long-term contracts, crucial for sustained earnings.

Financial Stability

A balanced financial position with manageable leverage provides stability and flexibility, supporting long-term operational and strategic initiatives.

Negative Factors

Revenue Decline

Declining revenue and profitability indicate challenges in maintaining market position and operational efficiency, impacting long-term growth prospects.

Profit Margin Contraction

Contracting profit margins suggest operational inefficiencies and pricing pressures, potentially affecting the company's ability to invest in growth and innovation.

Cash Flow Instability

Inconsistent free cash flow can hinder the company's ability to fund new projects and manage capital expenditures, impacting long-term strategic growth.

Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model

Company Description

Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.

How the Company Makes Money

Mangalam Drugs & Organics Ltd. generates revenue primarily through the production and sale of active pharmaceutical ingredients (APIs) and intermediates to pharmaceutical companies. The company's revenue model is based on wholesale and bulk sales, where it supplies its products to large pharmaceutical firms that utilize these inputs in their formulations. Key revenue streams include contracts with domestic and international clients, which provide a steady demand for its products. Additionally, MANGALAM may engage in partnerships with other companies for research and development, leading to potential royalties or revenue sharing agreements. The company's commitment to quality and compliance with regulatory standards enhances its reputation, allowing it to command competitive pricing and secure long-term contracts, which are crucial for its earnings.

Mangalam Drugs & Organics Ltd. Financial Statement Overview

Summary

Mangalam Drugs & Organics Ltd. reflects a mixed financial performance with challenges in sustaining revenue growth and profitability. The balance sheet displays an adequate financial position with manageable debt levels, while cash flow management reveals fluctuations, particularly in free cash flow generation. The company needs to address profitability and cash flow stability to improve its financial health.

Income Statement

Mangalam Drugs & Organics Ltd. shows fluctuating revenue and profit margins. The most recent year indicates a decline in total revenue and net income, impacting the net profit margin negatively. EBIT and EBITDA margins have also contracted, reflecting challenges in maintaining profitability. Despite a prior trend of increasing revenue, the recent performance suggests instability in revenue growth and profitability.

Balance Sheet

The company's debt-to-equity ratio and equity ratio indicate a balanced financial position with manageable leverage. A consistent stockholders' equity and adequate asset management demonstrate financial stability. However, the increase in total debt over recent years suggests potential risk if revenue declines persist.

Cash Flow

Operating cash flow has shown improvement although free cash flow remains inconsistent. The operating cash flow to net income ratio indicates strong cash generation relative to net income, but negative free cash flow in several periods signals potential challenges in investing activities and capital expenditure management.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.98B	3.18B	3.67B	3.70B	4.47B	3.80B
Gross Profit	1.26B	1.50B	188.12M	287.77M	546.89M	976.69M
EBITDA	228.74M	363.25M	174.95M	259.54M	451.84M	550.15M
Net Income	-97.62M	67.21M	-90.72M	12.70M	196.57M	279.71M
Balance Sheet
Total Assets	0.00	3.66B	3.34B	3.60B	3.28B	2.64B
Cash, Cash Equivalents and Short-Term Investments	25.89M	25.89M	11.87M	26.88M	19.55M	5.92M
Total Debt	0.00	962.30M	1.07B	885.47M	879.04M	697.06M
Total Liabilities	-1.49B	2.17B	1.98B	2.08B	1.78B	1.33B
Stockholders Equity	1.49B	1.49B	1.36B	1.52B	1.51B	1.31B
Cash Flow
Free Cash Flow	0.00	223.93M	-79.20M	116.09M	-19.60M	-38.86M
Operating Cash Flow	0.00	425.94M	39.13M	395.23M	257.09M	275.50M
Investing Cash Flow	0.00	-194.72M	-118.27M	-221.72M	-273.26M	-312.85M
Financing Cash Flow	0.00	-217.12M	52.27M	-166.17M	29.79M	26.98M

Mangalam Drugs & Organics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 28.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Negative. The current price of 28.07 is below the 20-day moving average (MA) of 57.46, below the 50-day MA of 65.78, and below the 200-day MA of 79.44, indicating a bearish trend. The MACD of -7.78 indicates Positive momentum. The RSI at 9.98 is Positive, neither overbought nor oversold. The STOCH value of 1.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANGALAM.

Mangalam Drugs & Organics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HPAL	64 Neutral	₹4.71B	27.97	―	0.88%	13.33%	-21.39%
BHAGERIA	63 Neutral	₹9.33B	18.31	―	0.82%	33.39%	85.08%
GANESHBE	63 Neutral	₹6.15B	15.52	―	―	-12.30%	-26.40%
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
KHAICHEM	58 Neutral	₹9.98B	15.57	―	―	67.43%	―
MANORG	54 Neutral	₹4.33B	18.68	―	―	22.53%	237.55%
MANGALAM	45 Neutral	₹519.48M	―	―	―	-24.55%	-310.57%

Mangalam Drugs & Organics Ltd. Corporate Events

Mangalam Drugs & Organics Ltd. Releases Unaudited Financial Results

Mangalam Drugs & Organics Ltd. announced the publication of its unaudited financial results for the quarter and half-year ending September 30, 2025. These results, approved by the Board of Directors, were published in Financial Express and Loksatta newspapers. The company reported a decrease in net profit compared to the previous year, which may impact its financial standing and investor confidence.

Mangalam Drugs Issues Corrigendum to 52nd Annual Report

Mangalam Drugs & Organics Ltd. has issued a corrigendum to its 52nd Annual Report, amending certain sections to include recent circulars from the Ministry of Corporate Affairs and the Securities and Exchange Board of India. These updates pertain to the conduct of Annual General Meetings through video conferencing and the extension of relaxations for printing and dispatching physical copies of annual reports, reflecting the company’s compliance with regulatory requirements.